Donald E Cutlip

Donald E Cutlip

Interventional Cardiology, Beth Israel Deaconess Medical Centre, Harvard Medical School

Biography

Dr Donald E Cutlip received his MD from the University of South Florid, followed by an internal medicine residency at the University of Connecticut and fellowships in cardiology and interventional cardiology at Beth Israel Hospital, Boston, MA. 

Dr Cutlip is Professor of Medicine at Harvard Medical School and a Vice Chair in the Department of Medicine at Beth Israel Deaconess Medical Center. He is Chief Medical Officer at Baim Institute for Clinical Research.

In 2006, he co-founded the Academic Research Consortium, which has promoted standardisation of endpoints and clinical trial methods for cardiac device clinical trials among academic research organisations, industry sponsors and regulatory agencies.

Read more

Articles by Donald E Cutlip

A Message From the Outgoing Editor-in-Chief

Donald E Cutlip,

Citation: US Cardiology Review 2018;12(2):77.

DOI:

https://doi.org/10.15420/usc.2018.14.1
Diabetes Drugs and Cardiovascular Event Reduction: A Paradigm Shift

Erik M Kelly, Donald E Cutlip,

Citation: US Cardiology Review 2018;12(1):46–50.

DOI:

https://doi.org/10.15420/usc.2017:35:1
Foreword

Donald E Cutlip,

Citation: US Cardiology Review 2018;12(1):7

DOI:

https://doi.org/10.15420/usc.2018.12.1.FO1
Clinical Trial Perspective: Optimizing Crossover From Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome (CAPITAL OPTICROSS)

Donald E Cutlip,

Citation: US Cardiology Review 2017;11(2):59–61.

DOI:

https://doi.org/10.15420/ucs.2017:10:1
Foreword

Donald E Cutlip,

Citation: US Cardiology Review 2017:11(2):51

DOI:

https://doi.org/10.15420/usc.2017:11:02:51
Foreword

Donald E Cutlip,

Citation: US Cardiology Review 2017;11(1):4

DOI:

https://doi.org/10.15420/usc.2017:11:1:4
When to Use Bioresorbable Vascular Scaffolds

Xiaoyu Yang, Mohamed Ahmed, Donald E Cutlip, et al

Citation: US Cardiology Review 2017;11(1):25–30

DOI:

https://doi.org/10.15420/usc.2017:3:2
Dual Anti-platelet Therapy after Coronary Stenting: Rationale for Personalized Duration of Therapy

Donald E Cutlip,

Citation: US Cardiology Review 2017;11(1):31–6

DOI:

https://doi.org/10.15420/usc.2017:7:2
Foreword

Donald E Cutlip,

Citation: US Cardiology Review 2016;10(2):53

DOI:

https://doi.org/10.15420/usc.2016:10.2.ED1
Foreword

Donald E Cutlip,

Citation: US Cardiology Review 2016:10(1):6-7

DOI:

https://doi.org/10.15420/usc.2016.10.1.6
Percutaneous Coronary Intervention in Patients with Diabetes and Multivessel or Left Main Disease - a Review

Donald E Cutlip,

Citation: Interventional Cardiology 2012;7(1):37–40

DOI:

https://doi.org/10.15420/icr.2012.7.1.37
Percutaneous Coronary Intervention in Patients with Diabetes and Multivessel or Left Main Disease - A Review

Donald E Cutlip,

Citation: US Cardiology 2012;9(2):108-11

DOI:

https://doi.org/10.15420/usc.9.2.108